Coherus Q3 net loss widens to $86.7M on 45% revenue decline; CIMERLI projected >$100M in 2023

Coherus Oncology, Inc.

2022-Q3 EPS reported -$3.00 revenue$165,690,000

Q3 2022 net revenue $45.4M (down from $82.5M YoY); net loss $86.7M ($1.11 loss per share).
GAAP EPS loss $1.11 vs $0.49 loss YoY; non-GAAP EPS loss $0.96 vs $0.34 loss.
CIMERLI launched Oct 3, 2022; 2023 net sales projected >$100M; leading biosimilar market share.
Toripalimab BLA target action date Dec 23, 2022; FDA inspections hindered by COVID travel restrictions.
Targeting profitability in 2024; planning 2023 launches of YUSIMRY, toripalimab, UDENYCA OBI.

item 2.02 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

Coherus Oncology, Inc. reported third quarter ended September 30, 2022 results: revenue $45.4 million, net income Net loss of $86.7 million, or $(1.11) per share, EPS $(1.11) per share.

Period: third quarter ended September 30, 2022
Revenue: $45.4 million
Net income: Net loss of $86.7 million, or $(1.11) per share
EPS: $(1.11) per share
Result: reported results

Exact text from the filing

Net revenue, consisting primarily of net sales of UDENYCA®, was $45.4 million

View on SEC.gov

39 earnings releases filed in the last 30 days. Browse all earnings releases →

Coherus Oncology, Inc. filing history →

Source: SEC EDGAR

accession 0001558370-22-016847

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.